Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jacobio Pharmaceuticals has announced the receipt of a significant upfront payment of RMB172.79 million from Allist, as part of an exclusive licensing-out agreement for two of its drugs, Glecirasib and JAB-3312. This financial boost is set to strengthen the company’s cash reserves and support the development of its drug pipeline. Investors are cautioned, however, that the success of the drugs’ development and market launch is not guaranteed.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.